Related Experiment Video
Updated: May 31, 2026
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Pharmacogenomics and multiple sclerosis: moving toward individualized medicine
Manuel Comabella1, Koen Vandenbroeck
1Centre d'Esclerosi Múltiple de Catalunya, CEM-Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. mcomabella@ir.vhebron.net
Current Neurology and Neuroscience Reports
|June 25, 2011
Summary
Pharmacogenomics research is identifying new biomarkers for multiple sclerosis (MS) therapies. These molecular markers aim to predict patient response and treatment risks, aiding neurologists in personalized medicine for MS management.
Area of Science:
- Pharmacogenomics
- Neuroimmunology
- Biomarker Discovery
Background:
- Despite existing disease-modifying therapies for multiple sclerosis (MS), many patients still face disease progression, relapses, and adverse effects.
- Identifying predictive biomarkers is crucial for optimizing treatment strategies and managing patient outcomes in MS.
Purpose of the Study:
- To review recent advancements in the pharmacogenomics of disease-modifying therapies for multiple sclerosis.
- To highlight the growing number of molecular markers for predicting treatment response and risks in MS patients.
Main Methods:
- Review of current research on gene expression, proteomic, and genomic approaches in MS pharmacogenomics.
- Analysis of reported molecular markers for predicting clinical response and adverse events associated with MS therapies.
Main Results:
- A diverse and increasing range of promising molecular markers for MS drug response have been reported.
- Most identified markers require further validation but show potential for clinical application.
Conclusions:
- Pharmacogenomic research is vital for developing personalized treatment strategies in multiple sclerosis.
- Future validation of these biomarkers will empower neurologists to make more informed decisions regarding MS therapy and patient management.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...